Kailera Therapeutics, Inc. Common Stock (KLRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kailera Therapeutics, Inc. Common Stock (KLRA) has a cash flow conversion efficiency ratio of -0.069x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-77.53 Million) by net assets ($1.12 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Kailera Therapeutics, Inc. Common Stock stock valuation for the company's overall valuation and market capitalisation.
Kailera Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2025–2025)
This chart illustrates how Kailera Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Kailera Therapeutics, Inc. Common Stock (KLRA) share price today for real-time trading data and today's change.
Kailera Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kailera Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Review Kailera Therapeutics, Inc. Common Stock financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Grandjoy Holdings Group Co Ltd
SHE:000031
|
-0.023x |
|
Savaria Corporation
TO:SIS
|
0.048x |
|
SES S. A.
PA:SESG
|
0.174x |
|
Tong Yang Industry Co Ltd
TW:1319
|
0.079x |
|
Kelt Exploration Ltd.
TO:KEL
|
0.048x |
|
Pegasus Hava Tasimaciligi AS
IS:PGSUS
|
0.189x |
|
SKYWORTH GRP UNSP.ADR/30
F:KYW0
|
N/A |
|
IBI Inv House
TA:IBI
|
0.094x |
Annual Cash Flow Conversion Efficiency for Kailera Therapeutics, Inc. Common Stock (2025–2025)
The table below shows the annual cash flow conversion efficiency of Kailera Therapeutics, Inc. Common Stock from 2025 to 2025. Also see KLRA total asset value for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-356.46 Million | $-120.21 Million | 0.337x | -- |
About Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral … Read more